• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

常染色体显性遗传性多囊肾病患者的 2 型糖尿病影响。

The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease.

机构信息

Division of Renal Diseases and Hypertension, Department of Medicine, School of Medicine, University of Colorado Denver, Aurora, Colorado, USA.

出版信息

Nephrol Dial Transplant. 2012 Jul;27(7):2862-5. doi: 10.1093/ndt/gfr744. Epub 2011 Dec 29.

DOI:10.1093/ndt/gfr744
PMID:22207329
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3398061/
Abstract

BACKGROUND

The epidemic of obesity and diabetes is increasing within the USA and worldwide. We have previously shown that body mass index has increased significantly in autosomal dominant polycystic kidney disease (ADPKD) subjects seen at our center in more recent years. However, the impact of Type II diabetes in ADPKD patients has not been well studied.

METHODS

This retrospective cohort study compared clinical characteristics in 44 pre-renal transplant patients with ADPKD and diabetes and 88 age- and sex-matched non-diabetic patients with ADPKD who were seen at the University of Colorado between 1977 and 2008. The primary outcomes in this study were renal volume determined by renal ultrasonography, renal function assessed by estimated glomerular filtration rate and time to onset of end-stage renal disease or death by Kaplan-Meier analyses.

RESULTS

Diabetic patients had significantly larger kidney volumes than those with ADPKD alone [geometric mean (95% confidence interval (CI)]: 2456 (1510-3992) versus 1358 (1186-1556) cm3, P=0.02. Among those whose age at hypertension diagnosis was known, the diabetic ADPKD patients had earlier median (95% CI) age at onset of hypertension compared to those with ADPKD alone: 32.5 (28-40) versus 38 (35-42) years, P=0.04. Diabetic ADPKD patients tended to have an earlier median age of death than those with ADPKD alone.

CONCLUSIONS

Patients with ADPKD and type II diabetes have larger renal volumes, earlier age at diagnosis of hypertension and may die at a younger age compared to those patients with ADPKD alone. This study emphasizes the importance of diabetes risk management in ADPKD.

摘要

背景

肥胖症和糖尿病的流行在美国和全球范围内不断加剧。我们之前的研究表明,近年来在我们中心就诊的常染色体显性多囊肾病(ADPKD)患者的体重指数显著增加。然而,Ⅱ型糖尿病对 ADPKD 患者的影响尚未得到充分研究。

方法

这项回顾性队列研究比较了 1977 年至 2008 年期间在科罗拉多大学就诊的 44 例接受肾移植前的 ADPKD 合并糖尿病患者和 88 例年龄和性别匹配的单纯 ADPKD 患者的临床特征。本研究的主要结局是通过肾脏超声确定的肾脏体积、通过估算肾小球滤过率评估的肾功能以及通过 Kaplan-Meier 分析确定的终末期肾病或死亡的发病时间。

结果

糖尿病患者的肾脏体积明显大于单纯 ADPKD 患者[几何均数(95%置信区间(CI)):2456(1510-3992)与 1358(1186-1556)cm3,P=0.02]。在已知高血压发病年龄的患者中,糖尿病 ADPKD 患者的高血压发病中位年龄(95%CI)早于单纯 ADPKD 患者:32.5(28-40)与 38(35-42)岁,P=0.04。糖尿病 ADPKD 患者的死亡中位年龄早于单纯 ADPKD 患者。

结论

与单纯 ADPKD 患者相比,ADPKD 合并Ⅱ型糖尿病患者的肾脏体积更大,高血压发病年龄更早,死亡年龄可能更早。本研究强调了在 ADPKD 患者中管理糖尿病风险的重要性。

相似文献

1
The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease.常染色体显性遗传性多囊肾病患者的 2 型糖尿病影响。
Nephrol Dial Transplant. 2012 Jul;27(7):2862-5. doi: 10.1093/ndt/gfr744. Epub 2011 Dec 29.
2
Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.极早发型常染色体显性多囊肾病患者的长期预后
Am J Nephrol. 2016;44(3):171-8. doi: 10.1159/000448695. Epub 2016 Aug 23.
3
Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation.常染色体显性多囊肾病作为肾移植后糖尿病的一个风险因素。
Kidney Int. 2005 Feb;67(2):714-20. doi: 10.1111/j.1523-1755.2005.67132.x.
4
Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.尿血管紧张素原除影像学分类外,还可预测常染色体显性遗传性多囊肾病的肾脏结局。
J Korean Med Sci. 2020 Jun 8;35(22):e165. doi: 10.3346/jkms.2020.35.e165.
5
Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.血管紧张素转换酶抑制剂与血管紧张素II受体阻滞剂作为常染色体显性多囊肾病一线治疗的成本效益
J Med Econ. 2017 Jul;20(7):715-722. doi: 10.1080/13696998.2017.1311266. Epub 2017 Apr 13.
6
RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.RAPID-ADPKD(亚太地区常染色体显性遗传性多囊肾病快速进展患者的回顾性流行病学研究):一项多中心、回顾性队列研究的研究方案。
BMJ Open. 2020 Feb 6;10(2):e034103. doi: 10.1136/bmjopen-2019-034103.
7
Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.常染色体显性多囊肾病(ADPKD)早期的肾脏结构:多囊肾病放射影像学研究联盟(CRISP)队列
Kidney Int. 2003 Sep;64(3):1035-45. doi: 10.1046/j.1523-1755.2003.00185.x.
8
Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.血清尿酸、肾脏体积与常染色体显性多囊肾病的进展。
Nephrol Dial Transplant. 2013 Feb;28(2):380-5. doi: 10.1093/ndt/gfs417. Epub 2012 Dec 4.
9
New onset diabetes after kidney transplantation in autosomal dominant polycystic kidney disease: a retrospective cohort study.常染色体显性多囊肾病肾移植后新发糖尿病:一项回顾性队列研究。
Nephrology (Carlton). 2012 Jan;17(1):89-96. doi: 10.1111/j.1440-1797.2011.01507.x.
10
Cisterna chyli in autosomal dominant polycystic kidney disease.常染色体显性多囊肾病中的乳糜池
J Magn Reson Imaging. 2015 Jan;41(1):142-8. doi: 10.1002/jmri.24527. Epub 2014 Jan 27.

引用本文的文献

1
Open-Label, Randomized, Controlled, Crossover Trial on the Effect of Dapagliflozin in Patients With ADPKD Receiving Tolvaptan.达格列净对接受托伐普坦治疗的常染色体显性多囊肾病患者疗效的开放标签、随机、对照、交叉试验
Kidney Int Rep. 2025 Jan 18;10(4):1063-1075. doi: 10.1016/j.ekir.2025.01.023. eCollection 2025 Apr.
2
Trigger Warning: How Modern Diet, Lifestyle, and Environment Pull the Trigger on Autosomal Dominant Polycystic Kidney Disease Progression.触发警告:现代饮食、生活方式和环境如何引发常染色体显性遗传性多囊肾病的进展。
Nutrients. 2024 Sep 27;16(19):3281. doi: 10.3390/nu16193281.
3
The Influence of Non-Pharmacological and Pharmacological Interventions on the Course of Autosomal Dominant Polycystic Kidney Disease.非药物和药物干预对常染色体显性遗传性多囊肾病病程的影响。
Nutrients. 2024 Sep 23;16(18):3216. doi: 10.3390/nu16183216.
4
Predictors of autosomal dominant polycystic kidney disease progression: a Brazilian single-center cohort.常染色体显性遗传性多囊肾病进展的预测因素:巴西单中心队列研究。
J Bras Nefrol. 2024 Jun 24;46(3):e20230040. doi: 10.1590/2175-8239-JBN-2023-0040en. eCollection 2024.
5
How Does ADPKD Severity Differ Between Family Members?常染色体显性多囊肾病在家庭成员之间的严重程度如何不同?
Kidney Int Rep. 2024 Feb 5;9(5):1198-1209. doi: 10.1016/j.ekir.2024.01.053. eCollection 2024 May.
6
Ketogenic metabolic therapy for chronic kidney disease - the pro part.用于慢性肾脏病的生酮代谢疗法——支持方观点。
Clin Kidney J. 2023 Nov 7;17(1):sfad273. doi: 10.1093/ckj/sfad273. eCollection 2024 Jan.
7
Cardiometabolic comorbidities in autosomal dominant polycystic kidney disease: a 16-year retrospective cohort study.常染色体显性遗传多囊肾病的心脏代谢合并症:一项 16 年回顾性队列研究。
BMC Nephrol. 2023 Nov 9;24(1):333. doi: 10.1186/s12882-023-03382-0.
8
Nonpharmacological Management of Autosomal Dominant Polycystic Kidney Disease.常染色体显性遗传性多囊肾病的非药物治疗。
Adv Kidney Dis Health. 2023 May;30(3):220-227. doi: 10.1053/j.akdh.2022.12.008.
9
Shared pathobiology identifies AMPK as a therapeutic target for obesity and autosomal dominant polycystic kidney disease.共同的病理生物学表明,AMPK是肥胖症和常染色体显性多囊肾病的治疗靶点。
Front Mol Biosci. 2022 Aug 23;9:962933. doi: 10.3389/fmolb.2022.962933. eCollection 2022.
10
A Systematic Review of Reported Outcomes in ADPKD Studies.常染色体显性多囊肾病(ADPKD)研究中报告结果的系统评价
Kidney Int Rep. 2022 Jul 5;7(9):1964-1979. doi: 10.1016/j.ekir.2022.06.012. eCollection 2022 Sep.

本文引用的文献

1
Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study.使用抗高血压药物与常染色体显性遗传多囊肾病患者的死亡率:一项基于人群的研究。
Am J Kidney Dis. 2011 Jun;57(6):856-62. doi: 10.1053/j.ajkd.2011.01.023. Epub 2011 Apr 2.
2
Metabolic syndrome components in patients with autosomal-dominant polycystic kidney disease.常染色体显性遗传多囊肾病患者的代谢综合征组分。
Kidney Blood Press Res. 2009;32(6):405-10. doi: 10.1159/000260042. Epub 2009 Nov 20.
3
The ratio between kidney volume and function increases with the progression of nephropathy in Type 2 diabetes.2型糖尿病肾病进展过程中,肾脏体积与功能的比值会升高。
Clin Nephrol. 2009 Oct;72(4):247-51. doi: 10.5414/cnp72247.
4
Renal and retinal effects of enalapril and losartan in type 1 diabetes.依那普利和氯沙坦对1型糖尿病患者肾脏和视网膜的影响
N Engl J Med. 2009 Jul 2;361(1):40-51. doi: 10.1056/NEJMoa0808400.
5
Activation of AMP-activated kinase as a strategy for managing autosomal dominant polycystic kidney disease.作为一种管理常染色体显性多囊肾病的策略,激活 AMP 激活的蛋白激酶。
Med Hypotheses. 2009 Dec;73(6):1008-10. doi: 10.1016/j.mehy.2009.05.043. Epub 2009 Jun 30.
6
A new equation to estimate glomerular filtration rate.一种估算肾小球滤过率的新公式。
Ann Intern Med. 2009 May 5;150(9):604-12. doi: 10.7326/0003-4819-150-9-200905050-00006.
7
Variation in age at ESRD in autosomal dominant polycystic kidney disease.常染色体显性多囊肾病患者终末期肾病发病年龄的差异。
Am J Kidney Dis. 2008 Feb;51(2):173-83. doi: 10.1053/j.ajkd.2007.10.037.
8
Autosomal dominant polycystic kidney disease reduces the risk of diabetes mellitus.
Arch Med Res. 2006 Apr;37(3):360-4. doi: 10.1016/j.arcmed.2005.07.009.
9
Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.代谢综合征的定义:美国国立心肺血液研究所/美国心脏协会关于定义相关科学问题会议的报告。
Circulation. 2004 Jan 27;109(3):433-8. doi: 10.1161/01.CIR.0000111245.75752.C6.
10
Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease.常染色体显性多囊肾病肾脏存活率的流行病学研究
Kidney Int. 2003 Feb;63(2):678-85. doi: 10.1046/j.1523-1755.2003.00776.x.